Research

You can find us on

This email address is being protected from spambots. You need JavaScript enabled to view it.

Charity number: 1144188

Trials & Projects

CURRENT UK CLINICAL TRIALS FOR BONE SARCOMA.

This listing, compiled by the British Sarcoma Group, includes current interventional multi-centre clinical trials for sarcoma which are in planning or open to recruitment in the UK.

Phase I and early Phase II single-centre trials, or trials brought into UK centres from overseas centres, may not be listed here; please contact the relevant trials centre if you wish to find out trials currently available.

Euro-Ewing (Open)

This trial is researching combination chemotherapy with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma. Sites are the CCLG and TCT units.

A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan In patients with advanced pre-treated Ewing's Sarcoma. This is being conducted across the UK including University College London Hospitals, Leeds, Christie, Royal Manchester Children's Hospital, Birmingham Children's Hospital, Newcastle, Sutton.

This trial is for children and adults up to the age of 50. We use the term ‘you’, but of course if you are a parent, we are referring to your child.

Ewing's sarcoma and peripheral Primitive Neuroectodermal Tumour (PNET) are similar types of cancer mostly affecting teenagers, young adults and children. These cancers mainly develop in or near the bones.

Ewing's sarcoma and PNET are usually treated with chemotherapy first. This is usually followed by surgery, radiotherapy and further chemotherapy, or a combination of these. This trial will compare several different combinations of chemotherapy drugs to see if they are more effective or have fewer side effects than the standard treatments normally used.

MAP chemotherapy helps stop the osteosarcoma coming back after surgery. Doctors think that adding other treatments to MAP after surgery may be even better. But they are not sure how well the new combinations of treatment will work. All treatments have side effects, so it is important that patients do not have treatments they don’t need.

In this trial, some patients will have MAP after surgery as normal (the ‘control group’). Some patients will have MAP plus ifosfamide and etoposide, called MAPIE. And some patients will have MAP plus interferon, called MAPifn. There is more information about the different groups in the ‘trial design’ section below.

This trial is looking at giving Treosulfan chemotherapy for children, young people and adults with Ewing’s sarcoma who have already had treatment.

This trial is for both adults and children. We use the term 'you' in this summary, but of course if you are a parent, we are referring to your child.

Ewing’s sarcoma is a type of cancer that mainly develops in, or near, the bones. It mainly affects teenagers, young adults and children.

Doctors usually treat Ewing’s sarcoma with chemotherapy. But if the tumour does not completely disappear, or continues to grow (is ‘refractory’) during chemotherapy, there are not many more treatments that doctors can use. So they are always looking for new ways to help in this situation.

Treosulfan is a chemotherapy drug similar to one already used to treat people with Ewing’s sarcoma. We know from research that Treosulfan can help people with other types of cancer. The researchers think that Treosulfan may help people who have already had treatment for their Ewing’s sarcoma.